Is Chemoendocrine Treatment without Alternative?
作者信息
Greil Richard
机构信息
IlIrd Medical Department at the Private Medical University Salzburg with Hematology, Medical Oncology, Hemostaseology, Infectious Disease and Rheumatology, Oncology Center, and Laboratory of Immunologic and Molecular Cancer Research, Salzburg, Austria.
出版信息
Breast Care (Basel). 2008;3(4):231-235. doi: 10.1159/000149558. Epub 2008 Aug 22.
Abstract
摘要
相似文献
1
Is Chemoendocrine Treatment without Alternative?化学内分泌治疗是唯一选择吗？
Breast Care (Basel). 2008;3(4):231-235. doi: 10.1159/000149558. Epub 2008 Aug 22.
2
Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR.乳腺癌对化疗内分泌和内分泌治疗反应中自噬和细胞凋亡的差异作用：JBCRG-07TR。
Int J Mol Sci. 2019 Feb 24;20(4):984. doi: 10.3390/ijms20040984.
3
Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy.在新辅助化疗与辅助化疗内分泌治疗的随机试验中，新辅助化疗后cerbB2表达对患者的预后相关性。
Breast Cancer Res Treat. 2000 Jan;59(2):171-5. doi: 10.1023/a:1006394317282.
4
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.早期乳腺癌中央坏死和纤维化的预后和预测影响：来自两个国际乳腺癌研究组化疗内分泌辅助治疗的随机试验结果。
Breast Cancer Res Treat. 2010 May;121(1):211-8. doi: 10.1007/s10549-009-0360-y. Epub 2009 Mar 12.
5
[Experimental chemo- and chemoendocrine therapy of human breast carcinomas serially transplanted into nude mice].[对连续移植到裸鼠体内的人乳腺癌进行化学和化学内分泌实验性治疗]
Nihon Geka Gakkai Zasshi. 1988 Jan;89(1):91-102.
6
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials.在一至三个淋巴结阳性、雌激素受体阳性的绝经后乳腺癌患者中，与单纯使用他莫昔芬相比，基于表柔比星的化疗内分泌辅助治疗可改善无病生存期：法国辅助治疗研究组02和07试验结果
Ann Oncol. 2006 Jan;17(1):65-73. doi: 10.1093/annonc/mdj022.
7
Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.对可手术乳腺癌患者按雌激素受体和绝经状态分层后进行辅助内分泌治疗、化疗及化疗联合内分泌治疗的直接比较。
Breast Cancer Res Treat. 1998 May;49(1):51-60. doi: 10.1023/a:1005901622642.
8
The Role of Chemoendocrine Agents in Postoperative Adjuvant Therapy for Breast Cancer: Meta-analysis of the First Collaborative Studies of Postoperative Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC).
Breast Cancer. 1994 Jul 30;P(P):P-P9. doi: 10.1007/BF02967368.
9
High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS?早期乳腺癌中高雌激素受体表达：化疗是否需要改善 RFS？
Breast Cancer Res Treat. 2011 Jul;128(1):273-81. doi: 10.1007/s10549-010-1334-9. Epub 2011 Jan 6.
10
Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy.早期乳腺癌患者接受内分泌治疗与化疗内分泌治疗随机分组后的疲劳和内分泌症状：来自 TAILORx 患者报告结局子研究的结果。
Cancer. 2022 Feb 1;128(3):536-546. doi: 10.1002/cncr.33939. Epub 2021 Oct 6.
本文引用的文献
1
Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.他莫昔芬与他莫昔芬联合抑制卵巢功能用于绝经前、淋巴结阴性、激素受体阳性乳腺癌女性的III期比较（E-3193，INT-0142）：东部肿瘤协作组的一项试验
J Clin Oncol. 2014 Dec 10;32(35):3948-58. doi: 10.1200/JCO.2014.55.6993. Epub 2014 Oct 27.
2
Commercialized multigene predictors of clinical outcome for breast cancer.用于乳腺癌临床结局的商业化多基因预测指标
Oncologist. 2008 May;13(5):477-93. doi: 10.1634/theoncologist.2007-0248.
3
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.雌激素受体表达与含多西他赛辅助化疗在淋巴结阳性乳腺癌患者中的疗效：一项汇总分析结果
J Clin Oncol. 2008 Jun 1;26(16):2636-43. doi: 10.1200/JCO.2007.14.9146.
4
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.CYP2D6的药物基因组变异与绝经后乳腺癌最佳辅助内分泌治疗的选择：一项建模分析
J Natl Cancer Inst. 2008 May 7;100(9):642-8. doi: 10.1093/jnci/djn100. Epub 2008 Apr 29.
5
An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.一种预测乳腺癌患者化疗反应的综合方法。
PLoS One. 2008 Apr 2;3(4):e1908. doi: 10.1371/journal.pone.0001908.
6
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.化疗内分泌与内分泌辅助治疗用于淋巴结阴性乳腺癌的比较：雌激素和孕激素受体中心评估表达的预测价值——国际乳腺癌研究组
J Clin Oncol. 2008 Mar 20;26(9):1404-10. doi: 10.1200/JCO.2007.10.6393.
7
A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.一种能够预测他莫昔芬治疗的原发性乳腺癌复发的基因表达特征。
Clin Cancer Res. 2008 Mar 15;14(6):1744-52. doi: 10.1158/1078-0432.CCR-07-1833.
8
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.在接受5年他莫昔芬辅助治疗后，依西美坦作为延长辅助治疗的获益：国家外科辅助乳腺和肠道项目B-33试验的意向性分析。
J Clin Oncol. 2008 Apr 20;26(12):1965-71. doi: 10.1200/JCO.2007.14.0228. Epub 2008 Mar 10.
9
Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.乳腺癌患者管理中的争议：绝经前女性的辅助内分泌治疗
J Clin Oncol. 2008 Feb 10;26(5):745-52. doi: 10.1200/JCO.2007.14.3016.
10
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.肿瘤Ki-67表达在两项针对淋巴结阴性乳腺癌辅助化疗内分泌治疗随机试验中的预测价值。
J Natl Cancer Inst. 2008 Feb 6;100(3):207-12. doi: 10.1093/jnci/djm289. Epub 2008 Jan 29.
Zotero 插件